Developer docs
API playgroundTry for free, no card

Search company profiles

KalVista Pharmaceuticals

Full company profile

uuid00007ax

Namestring
KalVista Pharmaceuticals
Legal namestring
KalVista Pharmaceuticals
Websiteurl
kalvista.com
Company typeenum
Public
Founded yearint
2012
Descriptiontext

KalVista Pharmaceuticals is a clinical and commercial-stage biopharmaceutical company that develops orally delivered small molecule protease inhibitors for rare diseases, with a primary focus on hereditary angioedema (HAE). The company's lead asset, EKTERLY (sebetralstat), is a plasma kallikrein inhibitor that blocks the kallikrein-kinin system (KKS) pathway mediating acute HAE attacks; it is the first and only oral on-demand treatment approved for HAE, holding regulatory clearances in the United States, United Kingdom, European Union, Japan, Australia, Switzerland, and Singapore following FDA approval on July 7, 2025. KalVista generates revenue from global net product sales of EKTERLY, distributed in the US through specialty pharmacy partner Orsini and internationally through regional commercialization partners (Kaken in Japan, Pendopharm in Canada, Multicare in Latin America), reaching 1,702 patient starts and 724 prescribing physicians representing approximately 20% of the US HAE patient population within roughly six months of launch. The company also runs the KONFIDENT-KID Phase 3 trial for pediatric patients aged 2-11 and maintains a preclinical oral Factor XIIa inhibitor program targeting HAE prophylaxis. KalVista was acquired by Italy-based Chiesi Group for $1.9 billion in June 2026 and now operates as a wholly owned subsidiary.

Short descriptiontext

KalVista Pharmaceuticals is a biopharmaceutical company that developed and commercialized EKTERLY (sebetralstat), the first and only oral on-demand treatment for hereditary angioedema attacks, serving HAE patients aged 12 and older across the US, Europe, and Japan.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersFramingham, United States
HQ citystring
Framingham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
hereditary angioedema treatment, oral protease inhibitors, rare disease therapeutics, plasma kallikrein inhibitors, small molecule pharmaceuticals
Industry2 codes
PRIMARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAH
Rare Cardiovascular & Vascular Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Hereditary Angioedema Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1EKTERLY Product Sales
TypeOne Time License
Description

Global net product revenue from commercial sales of EKTERLY (sebetralstat) following regulatory approvals. Generated $49.1 million in global net product revenue for the eight months ended December 31, 2025, driven by US commercial launch on July 7, 2025, with international expansion to Germany and Japan.

stocktitan.net
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations
Pricing details1 tier
1Prescription pharmaceutical product for HAE patients
ModelOtherBilling cadencePay-as-you-go
Notes

Pricing not publicly disclosed - distributed through specialty pharmacy partners with insurance coverage and patient support programs such as KalVista Cares

kalvista.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1EKTERLY (sebetralstat)
Description

First and only oral on-demand treatment for hereditary angioedema (HAE) attacks, approved in the US, UK, EU, Japan, and other markets

kalvista.com
+2 more records
Core offering1 text field

KalVista Pharmaceuticals develops, manufactures, and commercializes oral small molecule protease inhibitor therapies, beginning with EKTERLY (sebetralstat) - the first and only oral, on-demand treatment for acute hereditary angioedema attacks in patients aged 12 and older. The company is also advancing a preclinical oral Factor XIIa inhibitor program for HAE prophylaxis and a pediatric clinical program (KONFIDENT-KID) for children aged 2-11, distributing globally through specialty pharmacy and regional pharmaceutical partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 93.7% of caregivers experienced anxiety about injectable treatments; 47% of pediatric patients required emergency room care
+4 more records
Product overview1 text field

KalVista Pharmaceuticals is a global biopharmaceutical company developing and delivering oral therapies for rare diseases, beginning with hereditary angioedema (HAE). The company's commercial product is EKTERLY (sebetralstat), the first and only oral on-demand treatment for HAE attacks, approved in the US (July 2025), UK, EU, Japan, and other markets. The pipeline includes an oral Factor XIIa inhibitor in preclinical development for HAE prophylaxis and other conditions. The company was acquired by Chiesi Group in June 2026 and operates as a wholly owned subsidiary.

Product and service4 records
1EKTERLY (sebetralstat)
CategoryPrescription oral HAE therapy
Description

First and only oral, on-demand plasma kallikrein inhibitor approved for the treatment of acute hereditary angioedema attacks in patients aged 12 and older. It provides a non-invasive alternative to injectable therapies, enabling patients to treat attacks without needles.

2KONFIDENT-KID (pediatric sebetralstat clinical program)
CategoryClinical development program
Description

Open-label Phase 3 clinical program evaluating sebetralstat in a proprietary oral disintegrating tablet formulation for on-demand treatment of hereditary angioedema attacks in pediatric patients aged 2-11.

3Oral Factor XIIa Inhibitor Program
CategoryPipeline / preclinical program
Description

Preclinical oral Factor XIIa inhibitor program being studied as a treatment for HAE prophylaxis, expanding the HAE portfolio to include prophylactic treatment, and exploring potential applications in inflammation and thrombosis.

4KalVista Cares
CategoryPatient support service
Description

Comprehensive patient support program offering personalized services for eligible patients prescribed EKTERLY, including help navigating insurance coverage, access support, and financial assistance.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-06-14
Description

Chiesi Group completed acquisition of KalVista Pharmaceuticals on June 11, 2026 for $1.9 billion ($27 per share), making KalVista a wholly owned subsidiary. The acquisition brings EKTERLY (sebetralstat) into Chiesi's rare disease portfolio, with regulatory approvals across US, UK, EU, Japan, and other markets.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-01-08
Description

Partnership to commercialize EKTERLY (sebetralstat) in Brazil, Argentina, Colombia, and Mexico. This marks KalVista's third commercial partnership in ten months, expanding access to the first oral on-demand HAE treatment across Latin America.

3Kaken Pharmaceutical
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-12-22
Description

Japan-based partner responsible for commercialization of EKTERLY in Japan following Ministry of Health, Labor and Welfare approval. The medication was listed on Japan's National Health Insurance drug reimbursement system.

pharmiweb.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-07-07
Description

Specialty pharmacy partner for EKTERLY in the United States, providing specialized distribution and patient support services for the rare disease medication.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-06-26
Description

Exclusive distribution agreement for sebetralstat in Canada, with Pendopharm managing regulatory approval and commercialization as the first oral on-demand HAE treatment in Canada.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Direct HAE competitor marketing Orladeyo (berotralstat), the first oral prophylactic HAE therapy. BioCryst and KalVista are the two pure-play oral HAE innovators competing in the same rare disease market with complementary on-demand vs. prophylaxis positioning.

TypeEmerging player
Description

Clinical-stage company developing oral bradykinin B2 receptor antagonists (PHVS416, PHVS719) for both HAE on-demand treatment and prophylaxis. Pharvaris is the most direct emerging competitor to EKTERLY with an overlapping oral HAE strategy.

TypeBroad incumbent
Description

Acquired Shire's HAE franchise including Takhzyro (lanadelumab) for HAE prophylaxis and Firazyr (icatibant) for on-demand treatment. Takeda is the dominant incumbent in HAE with multiple established therapies competing directly with EKTERLY's on-demand positioning.

TypeBroad incumbent
Description

Rare disease specialist that markets Cinryze (C1-inhibitor replacement) for HAE prophylaxis outside the US. Sobi's established HAE franchise and rare disease commercial infrastructure make it a relevant peer in the broader rare disease therapeutics space.

TypeBroad incumbent
Description

Plasma-derived therapy leader marketing Berinert (C1-esterase inhibitor) and Haegarda for HAE treatment. CSL Behring's established plasma fractionation infrastructure and HAE franchise position it as a key incumbent competing with oral therapies like EKTERLY.

TypeEmerging player
Description

Antisense oligonucleotide platform company developing therapies for rare diseases, including a Factor XI antisense program relevant to the thrombosis space that KalVista's Factor XIIa program also targets. Comparable as a small-cap rare disease innovator.

TypeBroad incumbent
Description

European specialty pharmaceutical company with a rare disease franchise including HAE treatments (Ruconest via Pharming partnership). Recordati's rare disease commercial infrastructure and European market presence are comparable to Chiesi's positioning relative to KalVista.

TypeBroad incumbent
Description

AstraZeneca's rare disease unit following acquisition of Alexion, with a leading franchise in complement-mediated diseases. The complement/kallikrein-kinin system overlap with HAE biology makes Alexion thematically relevant to KalVista's therapeutic approach.

TypeBroad incumbent
Description

Commercial-stage rare disease leader (cystic fibrosis, sickle cell) that recently expanded into broader rare disease therapeutics. Vertex's track record of taking oral small molecules from rare disease R&D through global commercialization is comparable to the trajectory KalVista has followed.

TypeBroad incumbent
Description

Italy-based global pharmaceutical company focused on rare diseases that acquired KalVista for $1.9B in June 2026. Chiesi's rare disease portfolio and global commercialization capabilities now absorb KalVista's assets, making it the parent context for forward evaluation.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

KalVista Pharmaceuticals

Hereditary Angioedema Therapeuticskalvista.com

KalVista Pharmaceuticals is a biopharmaceutical company that developed and commercialized EKTERLY (sebetralstat), the first and only oral on-demand treatment for hereditary angioedema attacks, serving HAE patients aged 12 and older across the US, Europe, and Japan.

What KalVista Pharmaceuticals does

KalVista Pharmaceuticals is a clinical and commercial-stage biopharmaceutical company that develops orally delivered small molecule protease inhibitors for rare diseases, with a primary focus on hereditary angioedema (HAE). The company's lead asset, EKTERLY (sebetralstat), is a plasma kallikrein inhibitor that blocks the kallikrein-kinin system (KKS) pathway mediating acute HAE attacks; it is the first and only oral on-demand treatment approved for HAE, holding regulatory clearances in the United States, United Kingdom, European Union, Japan, Australia, Switzerland, and Singapore following FDA approval on July 7, 2025. KalVista generates revenue from global net product sales of EKTERLY, distributed in the US through specialty pharmacy partner Orsini and internationally through regional commercialization partners (Kaken in Japan, Pendopharm in Canada, Multicare in Latin America), reaching 1,702 patient starts and 724 prescribing physicians representing approximately 20% of the US HAE patient population within roughly six months of launch. The company also runs the KONFIDENT-KID Phase 3 trial for pediatric patients aged 2-11 and maintains a preclinical oral Factor XIIa inhibitor program targeting HAE prophylaxis. KalVista was acquired by Italy-based Chiesi Group for $1.9 billion in June 2026 and now operates as a wholly owned subsidiary.

KalVista Pharmaceuticals firmographics

Firmographics
Name
KalVista Pharmaceuticals
Legal name
KalVista Pharmaceuticals
Website
https://kalvista.com
Company type
Public
Founded year
2012
Operating status
Acquired
Headcount range
101–250 employees
Short description
KalVista Pharmaceuticals is a biopharmaceutical company that developed and commercialized EKTERLY (sebetralstat), the first and only oral on-demand treatment for hereditary angioedema attacks, serving HAE patients aged 12 and older across the US, Europe, and Japan.
Ownership category
akta.pro rank

KalVista Pharmaceuticals industry classification

Industry
Product category
Hereditary Angioedema Therapeutics
NAICS
Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAH
Rare Cardiovascular & Vascular Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Hereditary angioedema treatment
  • Oral protease inhibitors
  • Rare disease therapeutics
  • Plasma kallikrein inhibitors
  • Small molecule pharmaceuticals

Where KalVista Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Framingham
HQ country
United States
HQ region
North America

Offices5 records

Markets served

KalVista Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations

Revenue model

  1. EKTERLY Product Sales: Global net product revenue from commercial sales of EKTERLY (sebetralstat) following regulatory approvals. Generated $49.1 million in global net product revenue for the eight months ended December 31, 2025, driven by US commercial launch on July 7, 2025, with international expansion to Germany and Japan.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goPrescription pharmaceutical product for HAE patients

Go-to-market motion1 record

Distribution channels5 records

Marketing channels5 records

KalVista Pharmaceuticals product offering

Product offering

Core offering

KalVista Pharmaceuticals develops, manufactures, and commercializes oral small molecule protease inhibitor therapies, beginning with EKTERLY (sebetralstat) - the first and only oral, on-demand treatment for acute hereditary angioedema attacks in patients aged 12 and older. The company is also advancing a preclinical oral Factor XIIa inhibitor program for HAE prophylaxis and a pediatric clinical program (KONFIDENT-KID) for children aged 2-11, distributing globally through specialty pharmacy and regional pharmaceutical partners.

Product overview

KalVista Pharmaceuticals is a global biopharmaceutical company developing and delivering oral therapies for rare diseases, beginning with hereditary angioedema (HAE). The company's commercial product is EKTERLY (sebetralstat), the first and only oral on-demand treatment for HAE attacks, approved in the US (July 2025), UK, EU, Japan, and other markets. The pipeline includes an oral Factor XIIa inhibitor in preclinical development for HAE prophylaxis and other conditions. The company was acquired by Chiesi Group in June 2026 and operates as a wholly owned subsidiary.

Differentiator

Problem solved

Functional benefit

Brands

  • EKTERLY (sebetralstat): First and only oral on-demand treatment for hereditary angioedema (HAE) attacks, approved in the US, UK, EU, Japan, and other markets
  • KalVista Cares
  • KONFIDENT-KID

Products and services

  • EKTERLY (sebetralstat) First and only oral, on-demand plasma kallikrein inhibitor approved for the treatment of acute hereditary angioedema attacks in patients aged 12 and older. It provides a non-invasive alternative to injectable therapies, enabling patients to treat attacks without needles.
  • KONFIDENT-KID (pediatric sebetralstat clinical program) Open-label Phase 3 clinical program evaluating sebetralstat in a proprietary oral disintegrating tablet formulation for on-demand treatment of hereditary angioedema attacks in pediatric patients aged 2-11.
  • Oral Factor XIIa Inhibitor Program Preclinical oral Factor XIIa inhibitor program being studied as a treatment for HAE prophylaxis, expanding the HAE portfolio to include prophylactic treatment, and exploring potential applications in inflammation and thrombosis.
  • KalVista Cares Comprehensive patient support program offering personalized services for eligible patients prescribed EKTERLY, including help navigating insurance coverage, access support, and financial assistance.

Quantifiable outcome

  • 93.7% of caregivers experienced anxiety about injectable treatments; 47% of pediatric patients required emergency room care
  • +4 more outcomes

Companies that use KalVista Pharmaceuticals

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

KalVista Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

KalVista Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered flagship and core.

  • Chiesi GroupflagshipStrategic or Co-development Partner · 14 June 2026Chiesi Group completed acquisition of KalVista Pharmaceuticals on June 11, 2026 for $1.9 billion ($27 per share), making KalVista a wholly owned subsidiary. The acquisition brings EKTERLY (sebetralstat) into Chiesi's rare disease portfolio, with regulatory approvals across US, UK, EU, Japan, and other markets.
  • Multicare PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 8 January 2026Partnership to commercialize EKTERLY (sebetralstat) in Brazil, Argentina, Colombia, and Mexico. This marks KalVista's third commercial partnership in ten months, expanding access to the first oral on-demand HAE treatment across Latin America.
  • Kaken PharmaceuticalcoreChannel Partner/ Reseller/ Distributor · 22 December 2025Japan-based partner responsible for commercialization of EKTERLY in Japan following Ministry of Health, Labor and Welfare approval. The medication was listed on Japan's National Health Insurance drug reimbursement system.
  • OrsinicoreChannel Partner/ Reseller/ Distributor · 7 July 2025Specialty pharmacy partner for EKTERLY in the United States, providing specialized distribution and patient support services for the rare disease medication.
  • Pendopharm (Pharmascience Inc.)coreChannel Partner/ Reseller/ Distributor · 26 June 2025Exclusive distribution agreement for sebetralstat in Canada, with Pendopharm managing regulatory approval and commercialization as the first oral on-demand HAE treatment in Canada.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

KalVista Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • BioCryst Pharmaceuticals: Direct HAE competitor marketing Orladeyo (berotralstat), the first oral prophylactic HAE therapy. BioCryst and KalVista are the two pure-play oral HAE innovators competing in the same rare disease market with complementary on-demand vs. prophylaxis positioning.

Emerging players

  • Pharvaris: Clinical-stage company developing oral bradykinin B2 receptor antagonists (PHVS416, PHVS719) for both HAE on-demand treatment and prophylaxis. Pharvaris is the most direct emerging competitor to EKTERLY with an overlapping oral HAE strategy.
  • Ionis Pharmaceuticals: Antisense oligonucleotide platform company developing therapies for rare diseases, including a Factor XI antisense program relevant to the thrombosis space that KalVista's Factor XIIa program also targets. Comparable as a small-cap rare disease innovator.

Broad incumbents

  • Takeda Pharmaceutical: Acquired Shire's HAE franchise including Takhzyro (lanadelumab) for HAE prophylaxis and Firazyr (icatibant) for on-demand treatment. Takeda is the dominant incumbent in HAE with multiple established therapies competing directly with EKTERLY's on-demand positioning.
  • Swedish Orphan Biovitrum (Sobi): Rare disease specialist that markets Cinryze (C1-inhibitor replacement) for HAE prophylaxis outside the US. Sobi's established HAE franchise and rare disease commercial infrastructure make it a relevant peer in the broader rare disease therapeutics space.
  • CSL Behring: Plasma-derived therapy leader marketing Berinert (C1-esterase inhibitor) and Haegarda for HAE treatment. CSL Behring's established plasma fractionation infrastructure and HAE franchise position it as a key incumbent competing with oral therapies like EKTERLY.
  • Recordati: European specialty pharmaceutical company with a rare disease franchise including HAE treatments (Ruconest via Pharming partnership). Recordati's rare disease commercial infrastructure and European market presence are comparable to Chiesi's positioning relative to KalVista.
  • Alexion / AstraZeneca Rare Disease: AstraZeneca's rare disease unit following acquisition of Alexion, with a leading franchise in complement-mediated diseases. The complement/kallikrein-kinin system overlap with HAE biology makes Alexion thematically relevant to KalVista's therapeutic approach.
  • Vertex Pharmaceuticals: Commercial-stage rare disease leader (cystic fibrosis, sickle cell) that recently expanded into broader rare disease therapeutics. Vertex's track record of taking oral small molecules from rare disease R&D through global commercialization is comparable to the trajectory KalVista has followed.
  • Chiesi Group: Italy-based global pharmaceutical company focused on rare diseases that acquired KalVista for $1.9B in June 2026. Chiesi's rare disease portfolio and global commercialization capabilities now absorb KalVista's assets, making it the parent context for forward evaluation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

KalVista Pharmaceuticals social profiles

Digital presence

KalVista Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

KalVista Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles11 records

KalVista Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

KalVista Pharmaceuticals M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about KalVista Pharmaceuticals

What does KalVista Pharmaceuticals do?

KalVista Pharmaceuticals develops, manufactures, and commercializes oral small molecule protease inhibitor therapies, beginning with EKTERLY (sebetralstat) - the first and only oral, on-demand treatment for acute hereditary angioedema attacks in patients aged 12 and older. The company is also advancing a preclinical oral Factor XIIa inhibitor program for HAE prophylaxis and a pediatric clinical program (KONFIDENT-KID) for children aged 2-11, distributing globally through specialty pharmacy and regional pharmaceutical partners.

Is KalVista Pharmaceuticals a public or private company?

KalVista Pharmaceuticals is a public company. It is classified as corporate owned and is currently acquired.

When was KalVista Pharmaceuticals founded?

KalVista Pharmaceuticals was founded in 2012. It employs 101 to 250 people.

Where is KalVista Pharmaceuticals based?

KalVista Pharmaceuticals is headquartered in Framingham, United States, in the North America region.

How does KalVista Pharmaceuticals make money?

One revenue line is on record: EKTERLY Product Sales.

Who are KalVista Pharmaceuticals's main competitors?

BioCryst Pharmaceuticals is listed as a direct peer. Emerging players are Pharvaris and Ionis Pharmaceuticals. Broad incumbents are Takeda Pharmaceutical, Swedish Orphan Biovitrum (Sobi), CSL Behring, Recordati, Alexion / AstraZeneca Rare Disease, Vertex Pharmaceuticals and Chiesi Group.

Does KalVista Pharmaceuticals have an API?

No public API is recorded for KalVista Pharmaceuticals.

What industry is KalVista Pharmaceuticals in?

KalVista Pharmaceuticals's product category is Hereditary Angioedema Therapeutics. Its primary akta.pro industry code is HLAIAIAN, Rare Pediatric & Congenital Disorder Therapies, with a secondary code of HLAIAIAH, Rare Cardiovascular & Vascular Disorder Therapies. Its NAICS code is 5417 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Stock TitanKalVista to present 5 sebetralstat studies at ACAAIKalVista Pharmaceuticals, a Chiesi Group company, presented five new clinical and real-world studies on sebetralstat at the ACAAI 2026 Annual Meeting in Phoenix. The presentations cover patient satisfaction, treatment switching, quality-of-life outcomes, and healthcare resource utilization in adolescents. The research underscores the value of integrating real-world evidence and patient-reported outcomes in HAE care.Mpo-magReza Zadno Joins Mobia Medical’s Board of DirectorsMobia Medical appointed Reza Zadno, Ph.D., as an independent director and member of its Compensation Committee. He previously led PROCEPT BioRobotics through its 2021 IPO and served at Avedro and Invuity. Zadno expressed support for Mobia's stroke therapy, Vivistim.pharmaphorumChiesi fills permanent CEO role with Flagship's KhougazianChiesi named David Khougazian as its new permanent CEO, effective October 15, replacing Jean-Marc Bellemin. He will lead the group's revenue growth strategy, targeting €6 billion annual revenue from €3.6 billion in 2025. The company recently completed a $1.9 billion buyout of KalVista Pharmaceuticals and Ekterly.BioSpaceChiesi Group Delivers Solid H1 2026 Performance, Combining Growth, Continued Investment in Innovation and Positive Economic Impact Across CommunitiesChiesi Group reported H1 2026 revenues of €1.89 billion, up 3.6% at constant exchange rates, driven by rare diseases and respiratory growth. The company invested €426 million in R&D (22.5% of sales) and completed the acquisition of KalVista Pharmaceuticals for hereditary angioedema treatment. EBITDA margin remained at 29.4%.StocktradersdailyPrice-Driven Insight from (KALV) for Rule-Based StrategyKalvista Pharmaceuticals Inc. (NASDAQ: KALV) uses AI models to generate trading strategies and real-time trading signals, with features including risk management and personalized alerts.NewswireDRI Healthcare Announces Receipt of Put Price on EKTERLYDRI Healthcare received approximately $178 million in put price on its royalty participation right in EKTERLY, completing the transaction after Chiesi's acquisition of KalVista. The royalty right has terminated, and the company said the outcome reflects disciplined underwriting and creates capacity for future opportunities.NewswireDRI Healthcare Reports Second Quarter 2026 Results and New Board AppointmentDRI Healthcare reported record Q2 2026 results with total income of $50.1 million and an adjusted EBITDA margin of 92%. The company exercised its put option on Ekterly for ~$178 million and paid a $75 million milestone for Lumvoa's FDA approval. A board appointment of Dr. Sheila Singh and Dr. Yasir Al-Wakeel was announced.European BiotechnologyChiesi retreats from Gossamer PAH programme after Phase 3 missChiesi returned all development and commercial rights to seralutinib to Gossamer Bio after the drug missed its Phase 3 primary endpoint. Chiesi will pay a final $5 million, while Gossamer retains worldwide rights and plans a US approval application in September. The application could receive an FDA decision in the third quarter of 2027.NewswireDRI Healthcare Announces Exercise of Put Option on EKTERLY®DRI Healthcare exercised its put option on EKTERLY royalty rights, repurchasing for about $178 million after Chiesi's acquisition of KalVista. Payment is expected by mid-August. Proceeds will be redeployed into biopharmaceutical investments.massliveA Framingham biotech just became a $1.9B Italian acquisition. Here’s the drug behind itChiesi Group finalized its $1.9B acquisition of KalVista Pharmaceuticals, gaining control of EKTERLY, the first oral on-demand treatment for hereditary angioedema. The drug, approved for adults and adolescents 12+, generated $49M in US sales in July 2025. The deal strengthens Chiesi's rare disease portfolio.